AnaptysBio (ANAB) Stock Price, News & Analysis

Company Overview

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases. The company uses its proprietary antibody discovery and engineering capabilities to develop therapeutic candidates, with programs advancing through clinical development and partnerships. Its research has historically included immuno-oncology programs as well as treatments for diseases such as rheumatoid arthritis and inflammatory bowel disease.

Founded in 2005 and headquartered in San Diego, California, AnaptysBio has also generated value through licensing and collaboration agreements. Its antibody-discovery platform contributed to dostarlimab, an anti-PD-1 therapy developed by Tesaro and now marketed by GSK as Jemperli for certain cancer indications. The company’s operations and clinical development activities are primarily centered in the United States, with studies and commercial partnerships extending internationally. AnaptysBio is led by Chief Executive Officer Hamza Suria.

Key Stats

• Today's Range: $53.62 to $54.80
• 50-Day Range: $50.29 to $69.81
• 52-Week Range: $12.98 to $72.36
• Volume: 394,070 shs
• Average Volume: 697,365 shs
• Market Capitalization: $1.61 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $79.85
• Consensus Rating: Moderate Buy

AnaptysBio Stock Analysis - MarketRank™

AnaptysBio scored higher than 57% of companies evaluated by MarketBeat, and ranked 431st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 11 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

AnaptysBio has a consensus price target of $79.85, representing about 47.8% upside from its current price of $54.04.

Amount of Analyst Coverage

AnaptysBio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AnaptysBio are expected to grow in the coming year, from ($2.06) to $2.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AnaptysBio is -49.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AnaptysBio is -49.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AnaptysBio has a P/B Ratio of 40.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.69% of the float of AnaptysBio has been sold short.

Short Interest Ratio / Days to Cover

AnaptysBio has a short interest ratio ("days to cover") of 15.59, which indicates bearish sentiment.

Change versus previous month

Short interest in AnaptysBio has recently increased by 1.78%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AnaptysBio does not currently pay a dividend.

Dividend Growth

AnaptysBio does not have a long track record of dividend growth.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: N/A

News Sentiment

AnaptysBio has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for AnaptysBio this week, compared to 6 articles on an average week.

Search Interest

3 people have searched for ANAB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

4 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AnaptysBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

AnaptysBio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 9/16/2026
• Next Earnings (Estimated): 9/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ANAB
• CIK: 1370053
• Web: www.anaptysbio.com
• Phone: (858) 362-6295
• Fax: N/A
• Employees: 104
• Year Founded: 2005

Price Target and Rating

• Average Price Target for AnaptysBio: $79.85
• High Price Target: $100.00
• Low Price Target: $50.00
• Potential Upside/Downside: +47.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.23 million
• Net Margins: -11.53%
• Pretax Margin: -11.46%
• Return on Equity: N/A
• Return on Assets: -7.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.58
• Quick Ratio: 7.58

Sales & Book Value

• Annual Sales: $234.60 million
• Price / Sales: 6.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.34 per share
• Price / Book: 40.53

Miscellaneous

• Outstanding Shares: 29,610,000
• Free Float: 20,281,000
• Market Cap: $1.61 billion
• Optionable: Optionable
• Beta: 0.71